lilly.com rank 685 |
Number of domains linking to lilly.com 9 | semantic flow 1.1 |
Number of links to lilly.com 15 | semantic flow 1.1 |
Number of domains linked from lilly.com 2 | semantic flow 0.27 |
Number of links from lilly.com 3 | semantic flow 0.27 |
Pages with highest topical PageRank pointing to domain.
url / atext / target url | |
---|---|
https://diatribe.org/fda-approves-first-ever-concentrated-mealtime-insulin announced ↳https://investor.lilly.com/releaseDetail.cfm?ReleaseID=914999 | diatribe.org |
http://lillydiabetes.com/about-lilly-diabetes.aspx see what s up and coming in our diabetes clinical development pipeline ↳http://www.lilly.com/SiteCollectionDocuments/Pipeline/Clinical%20Development%20Pipeline/8. | lillydiabetes.com |
On-topic pages from domain with highest topical PageRank.
title / url | |||||||||
---|---|---|---|---|---|---|---|---|---|
Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events (NYSE:LLY) https://investor.lilly.com/releasedetail.cfm?ReleaseID=928280 | 0.19 | 0.99 | 16 | 2 | 2 | 2 | 1 | 1 | |
FDA Approves Basaglar® (insulin glargine injection), a Long-Acting Insulin Treatment (NYSE:LLY) https://investor.lilly.com/releaseDetail.cfm?ReleaseID=947336 | 0.19 | 1 | 18 | 4 | 4 | 4 | 1 | 1 |
On-topic pages from domain with highest topical PageRank having a few outgoing links and domains.
title / url | |||||||||
---|---|---|---|---|---|---|---|---|---|
FDA Approves Basaglar® (insulin glargine injection), a Long-Acting Insulin Treatment (NYSE:LLY) https://investor.lilly.com/releaseDetail.cfm?ReleaseID=947336 | 0.19 | 1 | 18 | 4 | 4 | 4 | 1 | 1 |
Relevant domains with most links to selected domain.
Relevant domains with most links from selected domain.
domain | |||
---|---|---|---|
http://prnewswire.com/ | 2 | 0.18 | prnewswire.com |
http://diabetesatlas.org/ | 1 | 0.09 | diabetesatlas.org |
Pages from domain with most relevant inbound links.
url | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
http://www.lilly.com/SiteCollectionDocuments/Pipeline/Clinical%20Development%20Pipeline/8. | 1 | 0.28 | 0.99 | 0.11 | -1 | - | -1 | -1 | -1 | -1 | 1 | 1 | |
https://investor.lilly.com/releaseDetail.cfm?ReleaseID=947336 | 1 | 0.19 | 0.96 | 0.08 | 1 | yes | 18 | 4 | 4 | 4 | 1 | 1 | |
http://www.lilly.com/diabetes/scholarship/ | 1 | 0.19 | 0.99 | 0.07 | -1 | - | -1 | -1 | -1 | -1 | 1 | 1 | |
http://www.lilly.com/diabetes/ | 1 | 0.19 | 1 | 0.07 | -1 | - | -1 | -1 | -1 | -1 | 1 | 1 | |
http://newsroom.lilly.com/releasedetail.cfm?releaseid=481632 | 1 | 0.18 | 0.92 | 0.07 | -1 | - | -1 | -1 | -1 | -1 | 1 | 1 | |
http://newsroom.lilly.com/releasedetail.cfm?releaseid=591404 | 1 | 0.18 | 0.91 | 0.07 | -1 | - | -1 | -1 | -1 | -1 | 1 | 1 | |
http://elms.xh1.lilly.com/Reconcile_Vet_label.pdf | 1 | 0.16 | 0.91 | 0.06 | -1 | - | -1 | -1 | -1 | -1 | 1 | 1 | |
http://uspl.lilly.com/humalog/humalog.html | 1 | 0.28 | 0.91 | 0.06 | -1 | no | -1 | -1 | -1 | -1 | 1 | 1 | |
http://lilly.com/ | 1 | 0.16 | 0.77 | 0.06 | -1 | - | -1 | -1 | -1 | -1 | 1 | 1 | |
https://investor.lilly.com/releasedetail.cfm?ReleaseID=1003887 | 1 | 0.17 | 0.7 | 0.03 | -1 | - | -1 | -1 | -1 | -1 | 1 | 1 |
Pages from domain with most likely on-topic outgoing links.
url | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
https://www.lilly.com/ | 5 | 0.19 | 0.04 | 0.01 | -1 | no | -1 | -1 | -1 | -1 | 1 | 1 | |
https://investor.lilly.com/releaseDetail.cfm?ReleaseID=947336 | 2 | 0.19 | 0.96 | 0.17 | 1 | yes | 18 | 4 | 4 | 4 | 1 | 1 | |
https://investor.lilly.com/releasedetail.cfm?ReleaseID=928280 | 1 | 0.19 | 0.96 | 0.1 | 0.99 | yes | 16 | 2 | 2 | 2 | 1 | 1 |
Similar domains to domain, based on inbound linking patterns from other relevant domains. This is also known in SEO as topical co-citation.